Posted by Michael Wonder on 08 Jul 2020
TLV is reviewing the subsidy of SGLT-2 inhibitors
8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors.
SGLT-2 inhibitors are medicines used, among other things, to treat adults with type 2 diabetes mellitus who are unable to control their blood sugar levels with metformin.
For the SGLT-2 inhibitor Jardiance (empagliflozin), a decision was made on 2 July 2020 to limitation its subsidy to use as an add-on to metformin therapy when metformin is not appropriate.
